Capricor Therapeutics to Present at Upcoming Investor Conferences

About this update from Caprock Mining Corp

Capricor Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.   Goldman Sachs 47th Annual Global Healthcare Conference, Miami, FL Fireside chat and investor meetings: Wednesday, June 10, at 10:00 a.m. ETWebcast: Click here Oppenheimer CNS and Neuro-Muscular Summit, Miami, FL Industry panel and investor meetings: Wednesday, June 10 A replay of the Goldman Sachs webcast will be available after the conclusion of the live event and will be accessible in the Investors section of the Company’s website. About Capricor Therapeutics Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (DMD), shown in clinical studies to preserve cardiac and skeletal muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X. Cautionary Note Regarding Forward-Looking Statements Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval, ...

View stock analysis, news, and events for Caprock Mining Corp